BioCentury
ARTICLE | Company News

GlaxoSmithKline, Iron Horse Therapeutics neurology news

November 16, 2015 8:00 AM UTC

Avalon Ventures and GlaxoSmithKline launched build-to-buy company Iron Horse Therapeutics with up to $10 million in series A funding and R&D support. The newco is developing small molecule inhibitors of EPH receptor A4 (EPHA4) to treat amyotrophic lateral sclerosis. Iron Horse has an exclusive license to the inhibitors from Sanford Burnham Prebys Medical Discovery Institute (La Jolla, Calif.). The company will be housed at Avalon’s COI Pharmaceuticals incubator. ...